Phase 2 study of preoperative chemotherapy with nab‐paclitaxel and gemcitabine followed by chemoradiation for borderline resectable or node‐positive pancreatic ductal adenocarcinoma

Phase 2 study of preoperative chemotherapy with nab‐paclitaxel and gemcitabine followed by chemoradiation for borderline resectable or node‐positive pancreatic ductal adenocarcinoma

Abstract Background Neoadjuvant treatment with nab‐paclitaxel and gemcitabine for potentially operable pancreatic adenocarcinoma has not been well studied in a prospective interventional trial and could down‐stage tumors to achieve negative surgical margins. Methods A single‐arm, open‐label phase 2...

Full description

Bibliographic Details
Main Authors: Emerson Y. Chen, Adel Kardosh, Nima Nabavizadeh, Bryan Foster, Skye C. Mayo, Kevin G. Billingsley, Erin W. Gilbert, Christian Lanciault, Aaron Grossberg, Kenneth G. Bensch, Erin Maynard, Eric C. Anderson, Brett C. Sheppard, Charles R. Thomas Jr, Charles D. Lopez, Gina M. Vaccaro, OHSU Gastrointestinal Cancer Disease Group
Format: Article
Language:English
Published: Wiley 2023-06-01
Series:Cancer Medicine
Subjects:
chemoradiation
clinical trial
gemcitabine
nab‐paclitaxel
neoadjuvant
pancreatic cancer
Online Access:https://doi.org/10.1002/cam4.5971

Internet

https://doi.org/10.1002/cam4.5971

Similar Items